Mount Sinai Study May Help Cancer Patients Keep Their Bladder - Mount Sinai
Mount Sinai Study May Help Cancer Patients Keep Their Bladder Mount Sinai
Bladder Cancer News
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy - The ASCO Post
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy The ASCO Post
Protara's bladder cancer therapy earns kudos amid choppy market reaction - FirstWord Pharma
Protara's bladder cancer therapy earns kudos amid choppy market reaction FirstWord Pharma
Breakthrough in Bladder Cancer: The KEYNOTE-B15 Clinical Trial - Targeted Oncology
Breakthrough in Bladder Cancer: The KEYNOTE-B15 Clinical Trial Targeted Oncology
Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months - Fierce Biotech
Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months Fierce Biotech
Experts Preview Practice-Changing Data Ahead of 2026 ASCO GU - CUREtoday.com
Experts Preview Practice-Changing Data Ahead of 2026 ASCO GU CUREtoday.com
Beam Therapeutics’ new PKU program; Protara’s bladder cancer data - Endpoints News
Beam Therapeutics’ new PKU program; Protara’s bladder cancer data Endpoints News
Exploring KDM6A as a Clinically Actionable Biomarker in Bladder Cancer - Sangeeta Goswami - UroToday
Exploring KDM6A as a Clinically Actionable Biomarker in Bladder Cancer - Sangeeta Goswami UroToday
ASCO GU 2026: 10 Most Promising Trials Shaping the Future of Genitourinary Oncology - Oncodaily
ASCO GU 2026: 10 Most Promising Trials Shaping the Future of Genitourinary Oncology Oncodaily
Evidence links polyploidy and senescence in bladder cells, with implications for cancer - Phys.org
Evidence links polyploidy and senescence in bladder cells, with implications for cancer Phys.org
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium - Business Wire
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium Business Wire
Is Tyra Biosciences’ (TYRA) ASCO GU Spotlight Quietly Reframing Its Bladder Cancer Pipeline Narrative? - simplywall.st
Is Tyra Biosciences’ (TYRA) ASCO GU Spotlight Quietly Reframing Its Bladder Cancer Pipeline Narrative? simplywall.st
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference - GlobeNewswire
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference GlobeNewswire
Study finds link between colorblindness and death from bladder cancer - Stanford Medicine
Study finds link between colorblindness and death from bladder cancer Stanford Medicine
Protara reports interim results from bladder cancer trial - Investing.com
Protara reports interim results from bladder cancer trial Investing.com
What's Going On With Protara Therapeutics Stock Tuesday? - Protara Therapeutics (NASDAQ:TARA) - Benzinga
What's Going On With Protara Therapeutics Stock Tuesday? - Protara Therapeutics (NASDAQ:TARA) Benzinga
Bladder Cancer - uofmhealth.org
Bladder Cancer uofmhealth.org
2026 ASCO GU Highlights: Bladder Cancer KEYNOTE-B15 - Targeted Oncology
2026 ASCO GU Highlights: Bladder Cancer KEYNOTE-B15 Targeted Oncology
Andrea Necchi: Multidisciplinary Effoert Needed for Treating Variant Histologies of Bladder Cancer - Oncodaily
Andrea Necchi: Multidisciplinary Effoert Needed for Treating Variant Histologies of Bladder Cancer Oncodaily
ASCO GU 2026 Preview: Highlights of Key Trials in Bladder, Kidney, Prostate, and Rare Cancers - Targeted Oncology
ASCO GU 2026 Preview: Highlights of Key Trials in Bladder, Kidney, Prostate, and Rare Cancers Targeted Oncology
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer - The New England Journal of Medicine
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer The New England Journal of Medicine
New drug developed at UC Davis offers hope to bladder cancer patients - University of California - Davis Health
New drug developed at UC Davis offers hope to bladder cancer patients University of California - Davis Health
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress - TMX Newsfile
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress TMX Newsfile
Conditional Approval for ANKTIVA in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - ImmunityBio - Oncodaily
Conditional Approval for ANKTIVA in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - ImmunityBio Oncodaily
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries - Business Wire
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries Business Wire
Experimental bladder cancer drug TARA-002 hits 68% complete response at 6 months - Stock Titan
Experimental bladder cancer drug TARA-002 hits 68% complete response at 6 months Stock Titan
Cells that communicate may help hinder bladder cancer from spreading - University of York
Cells that communicate may help hinder bladder cancer from spreading University of York
TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - TradingView
TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer TradingView
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients - Business Wire
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients Business Wire
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients - Memorial Sloan Kettering Cancer Center
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients Memorial Sloan Kettering Cancer Center
Ashish M. Kamat: New IBCG Consensus on Optimal Management of Muscle-Invasive Bladder Cancer - Oncodaily
Ashish M. Kamat: New IBCG Consensus on Optimal Management of Muscle-Invasive Bladder Cancer Oncodaily
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up - Zacks Investment Research
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up Zacks Investment Research
Bladder Cancer: What You Need to Know - CU Anschutz newsroom
Bladder Cancer: What You Need to Know CU Anschutz newsroom
New cancer drug ANKTIVA reaches Saudi patients within 60 days - Stock Titan
New cancer drug ANKTIVA reaches Saudi patients within 60 days Stock Titan
Bladder Cancer Remission Rate: What Patients Need to Know in 2025 - Oncodaily
Bladder Cancer Remission Rate: What Patients Need to Know in 2025 Oncodaily
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial - The Lancet
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial The Lancet
ImmunityBio wins EU nod for bladder cancer dug (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio wins EU nod for bladder cancer dug (IBRX:NASDAQ) Seeking Alpha
Biliary Tract Cancers Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Biliary Tract Cancers Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight StreetInsider
Bladder cancer awareness: Survivors and doctors highlight early signs - WKRC
Bladder cancer awareness: Survivors and doctors highlight early signs WKRC
USC study suggests type 1 diabetes may significantly raise bladder cancer risk - Keck School of Medicine of USC
USC study suggests type 1 diabetes may significantly raise bladder cancer risk Keck School of Medicine of USC